ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2014

Jun 16, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2014-06-12

Reporting Person: Cormack Scott Daniel (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-06-12	Restricted Stock Unit (RSU)	$	A	37500	Acquired		Common Stock (37500)	Direct
2014-06-12	Restricted Stock Unit (RSU)	$	A	37500	Acquired	2016-07-30	Common Stock (37500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64980	Direct

Footnotes

F1: The reporting person no longer has a reportable beneficial interest in 7,077 shares of common stock held by his former spouse or 50,355 shares of common stock held by Trycor Investment Trust, of which the reporting person no longer serves as a co-trustee.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement.

F3: Pursuant to the terms of the RSU, the total underlying shares vest in four equal annual installments on the later of (i) each anniversary of the grant date and (ii) the first day thereafter during which the issuer's trading window is open, subject to the reporting person's provision of service to the issuer on each vesting date.

F4: The RSUs expire 30 days from the date they vest.

F5: Pursuant to the terms of the RSU, the total underlying shares vest if and when certain performance criteria relating to the issuer are met, subject to the reporting person's provision of service to the issuer on each vesting date, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones.